| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 29,616 | 38,344 | ||
| Restricted cash | 912 | - | ||
| Accounts receivable | 523 | 372 | ||
| Refundable research income tax credits | 4,602 | 4,604 | ||
| Prepaid expenses and other current assets | 8,423 | 6,573 | ||
| Total current assets | 44,076 | 49,893 | ||
| Property and equipment, net | 14,794 | 15,733 | ||
| Operating lease right-of-use assets | 14,428 | 15,061 | ||
| Refundable research income tax credits, non-current | 14,474 | 14,481 | ||
| Other non-current assets | 871 | 890 | ||
| Restricted cash | 0 | 1,500 | ||
| Total assets | 88,643 | 97,558 | ||
| Accounts payable | 15,556 | 10,740 | ||
| Accrued compensation and employee benefits | 17,145 | 15,425 | ||
| Other accrued liabilities | 9,868 | 13,938 | ||
| Deferred revenues | 7,556 | 7,556 | ||
| Total current liabilities | 50,125 | 47,659 | ||
| Deferred revenues, non-current | 5,874 | 5,874 | ||
| Long-term portion of lease liabilities | 25,424 | 23,461 | ||
| Other non-current liabilities | 977 | 962 | ||
| Total liabilities | 82,400 | 77,956 | ||
| Preferred stock | 0 | 0 | ||
| Common stock | 3,220 | 2,728 | ||
| Additional paid-in capital | 1,594,298 | 1,573,233 | ||
| Accumulated deficit | -1,589,830 | -1,554,900 | ||
| Accumulated other comprehensive loss | -1,445 | -1,459 | ||
| Total stockholders equity | 6,243 | 19,602 | ||
| Total liabilities and stockholders equity | 88,643 | 97,558 | ||
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)